Brazil's Cold Chain Revolution: Peli and Polar Forge Key Alliance

MAPLE GROVE, Minn. – March 02, 2026 – A landmark partnership announced today is set to reshape the landscape of pharmaceutical logistics in Latin America's largest economy. Global temperature-controlled packaging leader Peli BioThermal is joining forces with Brazil's Polar Group, a dominant force in regional cold chain solutions. The strategic alliance aims to significantly upgrade the infrastructure for transporting life-saving, temperature-sensitive medicines across Brazil, a market experiencing explosive growth and increasing regulatory scrutiny.

Through this collaboration, Polar Group will serve as the in-country provider for Peli BioThermal’s portfolio of reusable and single-use thermal shippers. This gives Brazilian pharmaceutical and biotech companies direct access to internationally recognized technologies, like the Crēdo line of shippers, backed by Polar Group's extensive local network and operational expertise.

A Strategic Response to a Booming Market

The timing of this partnership is no coincidence. Brazil's pharmaceutical market is one of the fastest-growing in the world, with the cold chain logistics segment alone projected to expand from USD 19.6 billion in 2025 to USD 33.8 billion by 2031, reflecting a compound annual growth rate of 9.2%. This surge is driven by a dramatic increase in the development and use of biologics, vaccines, and advanced cell and gene therapies—products that are not only high-value but also exceptionally fragile, demanding unbroken, strictly controlled temperature conditions from factory to patient.

This alliance directly addresses that critical need. "Brazil is an important and growing life sciences market, and it requires partners who share our commitment to quality and reliability," said Sam Herbert, CEO of Peli BioThermal, in the official announcement. "Polar Group brings strong technical capability and deep understanding of the market. Together, we are strengthening the cold chain infrastructure that supports the safe delivery of temperature-sensitive therapies to patients."

For Polar Group, a company with over two decades of leadership in the region, the partnership represents a significant technological leap. "This partnership takes us to a new technological level in the Brazilian cold chain," stated Paulo Vitor de Andrade, CEO of Polar Group. "By incorporating solutions aligned with the strictest international standards, we strengthened our growth strategy and consolidated the Polar Group as a reference in high performance, regulatory compliance and innovation in Latin America."

Navigating Brazil's Complex Regulatory Framework

A key driver for adopting such high-performance solutions is Brazil's stringent regulatory environment. The country's National Health Surveillance Agency, ANVISA, enforces rigorous standards for the transportation of pharmaceuticals, most notably through its resolution RDC 430/2020. This regulation mandates comprehensive good distribution practices, including temperature mapping validation of transport routes, continuous real-time monitoring, and a shared responsibility model that holds every entity in the supply chain accountable for product integrity.

Failure to comply can result in significant financial penalties and, more importantly, can compromise the efficacy and safety of medicines. The Peli BioThermal-Polar Group alliance is strategically positioned to provide a turnkey solution for companies navigating this complex landscape. Peli’s systems are designed to meet and exceed these international standards, offering validated performance across ambient, refrigerated, frozen, and deep-frozen temperature ranges. By combining these proven systems with Polar Group’s on-the-ground validation and logistics services, the partnership offers a powerful guarantee of compliance and quality assurance.

This move effectively raises the barrier for competitors and sets a new benchmark for pharmaceutical logistics in the country, moving beyond basic refrigerated transport to a more holistic, data-driven approach to ensuring product safety.

Broader Impacts on Public Health and a Global Strategy

Beyond the business implications, the strengthening of Brazil's cold chain has profound consequences for public health. Ensuring the integrity of vaccines, insulin, oncology drugs, and clinical trial materials means greater access to effective treatments for millions of Brazilians. A robust logistics network is the final, critical link in the chain that connects pharmaceutical innovation to patient well-being. By minimizing the risk of temperature excursions that can render expensive and life-saving drugs useless, the partnership directly contributes to a more resilient and reliable national healthcare system.

This move also highlights Peli BioThermal’s proven global expansion strategy. Rather than building a network from scratch, the company consistently partners with established regional leaders who possess deep market knowledge and an existing operational footprint. This model, successfully deployed in other key markets across Europe and Asia, allows for rapid market penetration and ensures that global technology is adapted to local needs and conditions.

Polar Group is an ideal partner in this model. As a recognized market leader in Latin America, its expertise extends beyond simple distribution. The company provides end-to-end cold chain solutions, including specialized storage and operational support, making it a deeply integrated player in Brazil's healthcare and life sciences ecosystem. The synergy between Peli BioThermal's world-class packaging technology and Polar Group's entrenched local presence creates a formidable offering designed to capture significant market share and drive the modernization of pharmaceutical transport across Brazil. This collaboration is not merely a distribution agreement; it is the foundation for a more advanced and secure pharmaceutical supply chain, poised to support the health of a nation.